QUSAC Pharma	BOT	URAL ANICAL RACTS			y Data Sheet Caffeine USP	
20	•	Health Hazard Fire Hazard Reactivity Personal Protection	2 1 0 E	5		
NFPA		HMIS		Personal Protective Equipment		
Section 1.0 Produc	t Identifi	cation and Comp	any Infori	mation		
Common Name or Trade Name	Natural	Caffeine USP 32 (Anhy	drous)	Catalog Number(s)	QPP-001- 01/02/03/04/05	
Manufacturer	645 bou	QUSAC PHARMA INC. 645 boul des Erables Valleyfield Quebec J6T 6G3 Canada		CAS#	58-08-2	
Common Name	Natural	Natural Caffeine		RTECS	EV6475000	
Synonyms	1,3,7-tri	1,3,7-trimethylxanthine		TSCA	TSCA 8(b) inventory: Caffeine	
IUPAC	1,3,7-tri	1,3,7-trimethypurine-2,6-dione				
Chemical Formula	C8H10N4	C8H10N4O2				
Emergency 24hrs	Canuted	Canutec 613-996-6666				
Information Business hours	QUSAC	QUSAC Pharma Inc. 450-371-2925				
Section 2.0 Compo	sition an	d Information on	Ingredien	its		
Name		CAS# LI		50	% by Weight	
Natural Caffeine		58-08-2 192		g/Kg	100	
Section 3.0 Hazard	s Identif	ication				
Emergency Overview						
WARNING! HARMFUL IS SW POSSIBLE BIRTH DEFECT HA				-	AND RESPIRATORY TRACT.	
210	•	Health Hazard Fire Hazard Reactivity Personal Protection	2 1 0 E	5 4		
Potential Health Effects						
QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3	Tel	Free : 1-877-463-3223 : (450) 371-2925 : (450) 371-0526		Q		

tea, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada

Tel : (450) 371-2925 Fax : (450) 371-0526 email : info@qusacpharma.com

Inhalation	Inhalation of dust may irritate the mucous membranes and respiratory tract. High concentrations may produce effects paralleling ingestion.		
Ingestion	Toxic. The adult mean lethal dose is approximately 10 g. Large doses may produce palpitation, excitement, insomnia, dizziness, headache and vomiting		
Skin Contact	Causes irritation to skin, Symptoms include redness, itching and pain		
Eye Contact	Causes irritation, redness and pain		
Chronic Exposure	Excessive use of caffeine may lead to digestive disturbances, constipation, palpitations, shortness of breath and depressed mental states. Possible teratogen. May cause congenital malformation in the fetus		
Section 4.0 First Aid	i Measures		
Inhalation	Remove to fresh air, If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention		
Ingestion	Induce vomiting immediately as directed by medical personnel. Never give anything by mouth to an unconscious person. Get medical attention		
Skin Contact	Immediately flush skin with plenty of water for at least 15 minutes. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.		
Eye Contact	Immediately flush eyes with plenty of water for at least 15 minutes, lifting lower an upper eyelids occasionally. Get medical attention immediately		
Section 5.0 Fire Fig	hting Measures		
Fire	As with most organic solids, fire is possible at elevated temperatures or by contact with an ignition source.		
Explosion	Fine dust dispersed in air in sufficient concentrations, an in the presence of an gnition source is a potential dust explosion hazard.		
Fire Extinguishing Media	Water spray, dry chemical, alcohol foam, or carbon dioxide		
Special Information	In the event of a fire, wear full protective clothing and NIOSH-approved self- contained breathing apparatus with full face piece operated in the pressure demand or other positive pressure mode.		
Section 6.0 Acciden	tal Release Measures		

Remove all sources of ignition. Ventilate area of spill. Wear appropriate personal protective equipment as specified in Section 8. Clean up spills in a manner that does not disperse dust into the air. Use non-sparking tools and equipment. Reduce airborne dust and prevent scattering by moistening with water. Pick up spill for recovery or disposal.

Section 7.0 Handling and Storage

Keep in tightly closed container, stored in a cool, dry, ventilated area. Protect against physical damage. Fiber drum containers must be kept dry and away from excessive moisture. Empty containers of this material may be hazardous when empty since they retain product residues (Dust, Solids); observe all warnings and precautions listed for the product.

Section 8.0 Exposure Controls/Personal Protection

Airborne Exposure Limits None established

QUSAC Pharma Incorporated, 645, boul. des Érables Valleyfield (Québec) J6T 6G3 Canada



Ventilation System	A system of local and/or general exhaust is recommended to keep employee exposures as low as possible. Local exhaust ventilation is generally preferred because it can control the emissions of the contaminant at its source, preventing dispersion of it into the general work area.				
Personal Respirators	NIOSH Approved, for conditions of use where exposure to the dust or mist is apparent, a half-face dust/mist respirator may be worn. For emergencies or instances where the exposure levels are not known, use a full-face positive-pressure, air-supplied respirator.				
Skin Protection	Wear impervious protective clothing, including boots, gloves, lab coat, apron or coveralls, as appropriate, to prevent skin contact.				
Eye Protection	Use chemical safety goggles and/or full face shield where dusting or splashing is possible.				
Section 9.0 Physica	l and Chemical P	roperties			
Appearance	Crystalline powde	er Ta	ste	Bitter. (Slight.)	
Molecular Weight	194.2 g/mole	Co	lor	White	
pH (1% soln/water)	6.9	So	lubility	1 gm in 46 ml water	
Melting Point	237°C to 239°C	Bo	iling Point	178°C (sublimes)	
Specific Gravity	1.23	Oc	lor	Odorless	
Section 10.0 Stability	/ and Reactivity D	Data			
Stability	The product is stable under normal conditions of use.				
Conditions of Instability	Excess heat				
Hazardous Decomposition	Burning may produce carbon monoxide, carbon dioxide, nitrogen oxides				
Hazardous Polymerization	Will not occur				
Incompatibilities	Incompatible with strong oxidizers, iodine silver salts, tannins, and strong solutions of caustic alkalis				
Section 11.0 Toxicol	ogical Informatio	n			
	Carcinogenic effects:	3 (Not clas	sifiable for humar	n.) by IARC.	
	Mutagenic effects: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. May cause damage to the following organs: heart, gastrointestinal tract, central nervous system (CNS).				
Chronic Effects on Humans	May cause cancer (tumorigen) based on animal studies. May cause reproductive and fetal effects. May cause digestive tract disturbances (increased gastric acid, and pepsin secretion and a decrease in lower esophageal sphincter pressure), cardiovascular disturbances. Since it is a CNS stimulant, it may also affect the Central Nervous System (CNS).				
Special Remarks on Toxicity	LD50 - Route: Oral; Dose: 192 mg/kg				
			5, 6		



Special Remarks on other Toxic Effects on Humans and Acute Potential Health Effects	May cause gastrointestinal (digestive) tract irritation with epigastric pain, abdominal cramps, nausea, vomiting and diarrhea. Affects metabolism and cardiovascular system including increase in metabolism, flushing, palpitations, rapid heart rate, dysrhythmias, ypotension, blood pressure elevation and weight loss, metabolic acidosis. May affect brain and behavior/central nervous system. Symptoms may include nervousness, anxiety, restlessness, insomnia, dizziness, tremor, seizures, convulsions, hallucinations, somnolence, toxic psychosis, tremors, convulsions, ataxia. May also affect blood, respiration (hyperventilation) and urinary system (mild increase in urinary volume and urinary sodium excretion), and may directly produce hypokalemia.		
Section 12.0 Ecologie	cal Information		
Products of Biodegradation	Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.		
Toxicity of the Products of Biodegradation	Products of degradation are less toxic than the product itself.		
Section 13.0 Disposa	I Considerations		
Waste must be disposed of i	n accordance with federal, state and local environmental Control regulations.		
Section 14.0 Transpo	rt Information		
TDG Act Canada Classification	Class 6.1 Toxic substances		
DOT Classificatio	Class 6.1 Toxic substances		
Identification (Shipping name)	Alkaloid, solid, n.o.s.		
Identification (Technical name)	(caffeine)		
TDG Special Provisions for Transport	Special Provision 16 regarding the use of Technical name and Shipping names.		
TDG and DOT (Pictogram) ADR (Europe) (Pictograms)	6		
Section 15.0 Transpo	rt Information		
Other Regulations	 OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the European Inventory of Existing Commercial Chemica Substances. 		
WHMIS (Canada)	Not controlled under WHMIS (Canada). Does not have a WHMIS classification		
DSCL (EEC)	R22- Harmful if swallowed. R40- Possible risks of irreversible effects. R63- Possible risk of harm to the fetus. S2- Keep out of the reach of children.		



HMIS (U.S.A.) DSCL (Europe) (Pictograms)	Health Hazard Fire Hazard Reactivity Personal Protection	2 1 0 E	
Section 16.0 Othe	er Information		
Validated by Q.C.	Dr. Khaled Abou-Zeid	Date	May 25, 2011
Verified by Q.A.	Peter K Booth	Date	May 29, 2011
Date last revision	June 01 2011	Exspires	June 01 2014

All chemicals may pose unknown hazards and should be used with caution. This Material Safety Data Sheet (MSDS) applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomes contaminated, it may pose hazards not mentioned in this MSDS.

It shall be the user's responsibility to develop proper methods of handling and personal protection based on the actual conditions of use. While this MSDS is based on technical data judged to be reliable, QUSAC Pharma Inc. assumes no responsibility for the completeness or accuracy of the information contained herein.

